Welcome to LookChem.com Sign In|Join Free
  • or
1-chloro-2-fluoro-3-iodo-4-methoxybenzene is a chemical with a specific purpose. Lookchem provides you with multiple data and supplier information of this chemical.

1402004-77-6

Post Buying Request

1402004-77-6 Suppliers

Recommended suppliers

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

1402004-77-6 Usage

Structure

A benzene ring substituted with chlorine, fluorine, iodine, and a methoxy group

Applications

a. Building block in the synthesis of organic chemicals and pharmaceuticals
b. Precursor in the production of agrochemicals and advanced materials

Physical state

Colorless to pale yellow liquid

Melting point

High melting point, making it suitable for various industrial applications

Hazardous nature

Should be handled with care as it can be hazardous if not used properly

Check Digit Verification of cas no

The CAS Registry Mumber 1402004-77-6 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,4,0,2,0,0 and 4 respectively; the second part has 2 digits, 7 and 7 respectively.
Calculate Digit Verification of CAS Registry Number 1402004-77:
(9*1)+(8*4)+(7*0)+(6*2)+(5*0)+(4*0)+(3*4)+(2*7)+(1*7)=86
86 % 10 = 6
So 1402004-77-6 is a valid CAS Registry Number.

1402004-77-6Relevant academic research and scientific papers

Discovery of a class of highly potent Janus Kinase 1/2 (JAK1/2) inhibitors demonstrating effective cell-based blockade of IL-13 signaling

Zak, Mark,Hanan, Emily J.,Lupardus, Patrick,Brown, David G.,Robinson, Colin,Siu, Michael,Lyssikatos, Joseph P.,Romero, F. Anthony,Zhao, Guiling,Kellar, Terry,Mendonca, Rohan,Ray, Nicholas C.,Goodacre, Simon C.,Crackett, Peter H.,McLean, Neville,Hurley, Christopher A.,Yuen, Po-wai,Cheng, Yun-Xing,Liu, Xiongcai,Liimatta, Marya,Kohli, Pawan Bir,Nonomiya, Jim,Salmon, Gary,Buckley, Gerry,Lloyd, Julia,Gibbons, Paul,Ghilardi, Nico,Kenny, Jane R.,Johnson, Adam

, p. 1522 - 1531 (2019)

Disruption of interleukin-13 (IL-13) signaling with large molecule antibody therapies has shown promise in diseases of allergic inflammation. Given that IL-13 recruits several members of the Janus Kinase family (JAK1, JAK2, and TYK2) to its receptor complex, JAK inhibition may offer an alternate small molecule approach to disrupting IL-13 signaling. Herein we demonstrate that JAK1 is likely the isoform most important to IL-13 signaling. Structure-based design was then used to improve the JAK1 potency of a series of previously reported JAK2 inhibitors. The ability to impede IL-13 signaling was thereby significantly improved, with the best compounds exhibiting single digit nM IC50’s in cell-based assays dependent upon IL-13 signaling. Appropriate substitution was further found to influence inhibition of a key off-target, LRRK2. Finally, the most potent compounds were found to be metabolically labile, which makes them ideal scaffolds for further development as topical agents for IL-13 mediated diseases of the lungs and skin (for example asthma and atopic dermatitis, respectively).

Novel Compounds for the Treatment of Hepatitis C

-

Paragraph 0083; 0094, (2013/08/15)

The disclosure provides compounds of formula I, including their salts, as well as compositions and methods of using the compounds. The compounds have activity against hepatitis C virus (HCV) and may be useful in treating those infected with HCV.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1 Customer Service

What can I do for you?
Get Best Price

Get Best Price for 1402004-77-6